In a significant development for the landscape of breast cancer treatment, IceCure Medical has officially received Institutional Review Board (IRB) approval from the West Cancer Center & Research Institute in Germantown, Tennessee. This regulatory milestone signals the commencement of patient enrollment for the "ChoICE Study," a post-marketing clinical trial designed to further validate the real-world efficacy of the ProSense cryoablation system.
As medical technology continues to shift toward minimally invasive, organ-sparing interventions, the ChoICE Study represents a pivotal effort to establish cryoablation as a standard-of-care alternative for specific patient populations—specifically women aged 70 and older who face early-stage, low-risk breast cancer.
Main Facts: The ChoICE Study Framework
The ChoICE Study is structured as a robust post-marketing assessment, aiming to enroll 400 patients across 30 distinct medical sites in the United States. The primary objective is to evaluate the clinical performance of the ProSense system, a cryoablation technology that utilizes liquid nitrogen to "freeze" and destroy cancerous tissue.
Key Study Parameters:
- Target Demographic: Women aged 70 and older.
- Indication: Biologically low-risk breast tumors measuring 1.5cm or smaller.
- Clinical Scope: The study focuses on patients who are candidates for endocrine therapy but for whom traditional surgical options may be contraindicated or undesirable due to age or co-morbidities.
- The Dual-Purpose Site Model: A unique aspect of the ChoICE rollout is that each of the 30 participating centers will serve two roles. They will act as data-gathering nodes for the clinical study while simultaneously offering ProSense cryoablation as a commercial treatment option for patients who do not fit the specific study criteria but still qualify for the procedure. This dual-track approach is designed to accelerate patient access to the technology.
Dr. Richard Gilmore, a breast surgical oncologist at the Margaret West Comprehensive Breast Center (part of the West Cancer Center & Research Institute), has been appointed to lead the study site in Tennessee, marking a critical anchor for the trial’s operational launch.
Chronology: From ICE3 to ChoICE
The path to the ChoICE Study is rooted in years of rigorous clinical research and regulatory navigation. The progression of IceCure Medical’s technology reflects the broader medical community’s increasing trust in cryoablation as a viable oncological tool.
The Foundation: The ICE3 Trial
Before the initiation of the ChoICE Study, IceCure conducted the landmark ICE3 trial. This study served as the primary clinical engine that propelled ProSense toward its current standing. The ICE3 trial evaluated the safety and efficacy of the device in early-stage, low-risk breast cancer patients, and the results were transformative.
Regulatory Milestone: FDA Authorization
Following the data generated by the ICE3 trial, the U.S. Food and Drug Administration (FDA) granted marketing authorization for ProSense. This approval was a major win for the medical device industry, as ProSense is currently the only cryoablation device authorized by the FDA for use in conjunction with endocrine therapy for this specific demographic.
The Present: Launching ChoICE
With the recent IRB approval at the West Cancer Center, the company has transitioned from the "pivotal trial" phase into "post-marketing surveillance." This phase is critical, as it bridges the gap between controlled clinical trial environments and the chaotic, varied reality of day-to-day hospital practice. By monitoring how the device performs across 30 diverse sites, IceCure aims to demonstrate long-term reliability and real-world success.
Supporting Data: Why Cryoablation Matters
The clinical rationale for the ChoICE Study rests on the compelling metrics observed in previous trials. Cryoablation is not merely about destroying the tumor; it is about preserving the patient’s quality of life, minimizing surgical trauma, and achieving high rates of local control.
Recurrence Rates and Clinical Efficacy
Data from the ICE3 trial revealed a 3.1% local recurrence rate for early-stage, low-risk breast cancer when treated with ProSense followed by standard-of-care endocrine therapy. This low recurrence rate is highly competitive with traditional lumpectomy outcomes, particularly in elderly populations where the risks associated with general anesthesia and surgery are significantly higher.
Patient and Physician Satisfaction
The metrics surrounding patient experience are equally telling. In surveys conducted during the ICE3 trial:
- 99.1% of patients reported satisfaction with the cosmetic outcome of the procedure.
- 97% of physicians indicated satisfaction with the aesthetic results, highlighting that cryoablation leaves minimal scarring compared to traditional surgical resection.
For patients aged 70 and above, the prospect of avoiding an operating room, general anesthesia, and the subsequent recovery period associated with breast surgery is a compelling value proposition. The ProSense system allows for the procedure to be performed in an outpatient setting, significantly reducing hospital stays and associated costs.
Implications for Modern Oncology
The launch of the ChoICE Study has profound implications for how healthcare systems approach the "over-treatment" of low-risk cancers.
Shift toward Organ-Sparing Surgery
For decades, surgical resection has been the gold standard for breast cancer. However, as the medical field moves toward personalized medicine, there is an increasing push to avoid surgery where possible for frail or elderly patients. ProSense represents a "minimally invasive surgical" approach. By utilizing extreme cold, the system triggers a localized immune response and necrosis of the tumor without the need for an incision or the removal of healthy breast tissue.
Expanding Market Access
By integrating the trial sites with a commercial rollout, IceCure is effectively democratizing access to high-tech oncology. Often, patients in rural or non-academic settings do not have access to the latest clinical trials. By mandating that study sites also provide the service to non-trial patients, IceCure is creating a nationwide infrastructure for cryoablation.
The Future of Cryoablation
IceCure Medical’s focus is not limited to breast cancer. The company’s platform—utilizing liquid nitrogen as the cooling agent—is being evaluated for a variety of oncology indications, including bone, kidney, and lung tumors. The success of the ChoICE Study could provide the "gold standard" validation needed to expand these indications globally, potentially positioning cryoablation as a primary treatment modality for solid tumors across the human body.
The Road Ahead: Overcoming Challenges
While the outlook for the ChoICE Study is optimistic, the researchers face several hurdles. The primary challenge will be patient recruitment. With 400 patients required across 30 sites, maintaining consistent data quality and ensuring that each site adheres to the protocol is a significant operational undertaking.
Furthermore, the integration of cryoablation into standard surgical oncology workflows requires a paradigm shift. Surgeons must be trained to view "freezing" as a legitimate clinical alternative to "cutting." The ChoICE Study serves as an educational tool for the oncology community, providing the real-world evidence required for surgeons to confidently recommend the procedure to their patients.
Conclusion
The initiation of the ChoICE Study at the West Cancer Center & Research Institute marks a turning point in the management of early-stage breast cancer. By combining the safety profile of the ICE3 trial with a broad, multi-center real-world study, IceCure Medical is positioning itself at the forefront of the minimally invasive oncology revolution.
As the study progresses, the medical community will be watching closely. If the results continue to mirror the success of previous trials, we may be witnessing the beginning of a new era—one where surgery is no longer the inevitable path for every cancer patient, and where the power of extreme cold becomes a standard, life-saving, and life-enhancing tool in the fight against cancer.
For the thousands of women aged 70 and older who face the diagnosis of low-risk breast cancer, the ChoICE Study is more than just a clinical trial; it is a promise of a future defined by less trauma, faster recovery, and the preservation of personal dignity.
About the Author
